None listed
Conditions
Interventions
Drug : Generic/Product Name: Chunghyuldan
Directions: Take 2 capsules once a day
Dosage: 2 capsules (600mg)
Route of administration: Oral administration
Duration: 30 days or more
Sponsors
Kyung Hee University Oriental Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Among patients who visited the Department of cardiology and neurology at Kyunghee University Korean Medicine Hospital from January 1, 2017 to December 31, 2020, those who met the following conditions: • Patients aged 19 years or older who were diagnosed with cerebral infarction (I63) by combining brain imaging tests (Brain CT or MR) and clinical symptoms • A person who has been prescribed and taken Chunghyuldan (hospital code: DHH333) for more than 30 days to prevent recurrence of ischemic stroke • A person who has been observed for more than 2 years after starting to take Chunghyuldan • A person who has administered antiplatelet agents and anticoagulants in combination
Exclusion criteria
Exclusion criteria: • A person who has undergone follow-up for more than 2 years but has insufficient medical records to determine whether there is a recurrence of cerebral infarction. • In the case principal investigators and sub-investigators judge that they are not appropriate for research and analysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence of ischemic stroke | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients' demographic data, Concomitant diseases, social history, Use of combined antiplatelet therapy,TOAST determined, period of Chunghyuldan administration, adverse effect | — |
Countries
Korea, Republic of
Contacts
Public ContactHan-Gyul Lee
KyungHee University Medical Center
Outcome results
None listed